J&J reported first-quarter revenue of $24.1 billion, up 9.9% year-over-year, beating analyst estimates of $23.6 billion
Adjusted earnings per share came in at $2.70, exceeding the consensus estimate of $2.66
The company raised its full-year 2026 revenue forecast to a midpoint of $100.8 billion, slightly above Wall Street's estimate of $100.6 billion
Strong growth in cancer drug Darzalex ($4.0 billion in quarterly sales, beating expectations of $3.4 billion) and psoriasis treatment Tremfya ($1.6 billion, exceeding expectations of $1.2 billion) offset steep declines in Stelara
Stelara sales fell approximately 60% year-over-year to $656 million due to biosimilar competition following patent expiration
CEO Joaquin Duato stated the company is 'delivering on its promise for a year of accelerated growth and impact' driven by 'multiple game-changing approvals this quarter'
The Innovative Medicine segment drove growth with worldwide operational sales up 7.4%, led by oncology and immunology drugs